Purpose To conduct a systematic review of the literature to detect the effect of anti-resorptive
drugs (ARDs) and their administration characteristics in the development of medication …

Objective Bisphosphonates and denosumab are both antiresorptive medications, each with
their own mechanism of action; yet both may result in the same adverse effect: medication …

Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often
occurs after dental-related interventions in patients undergoing treatment with …

Purpose Details regarding risk factors, onset, and outcomes for denosumab-related
osteonecrosis (DRONJ) are sparse. This study examines the clinical characteristics and …

Medication‐related osteonecrosis of the jaw (MRONJ) is a serious complication in patients
receiving antiresorptive therapies for bone neoplastic localizations and osteoporosis. The …

Introduction Osteonecrosis of the jaw associated with bisphosphonates is currently called
medication‐related osteonecrosis of the jaw (MRONJ), given that in addition to …

Introduction Bisphosphonates are used in the treatment of osteoporosis and bone
metastases. They inhibit osteoclast function, thereby decreasing bone resorption. A side …

Denosumab, a monoclonal antibody against the receptor activator for nuclear factor–kappa
B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast …

Purpose There is much concern about the increasing number of patients with medication-
related osteonecrosis of the jaw (MRONJ), and many studies have been published in an …

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to
inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human …